The costs of amyotrophic lateral sclerosis, according to type of care

References

• Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995; 118: 707–19
   PubMed Web of Science ®Google Scholar
• Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001; 191: 3–9
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995–1997: a population-based study. Neurology. 1999; 52: 504–9
   PubMed Web of Science ®Google Scholar
• van den Berg JP, Kalmijn S, Lindeman E, Wokke JHJ, van den Berg LH. Rehabilitation care for patients with ALS in the Netherlands. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4: 186–90
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Lowe S. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature. Pharmacoeconomics. 2002; 20: 367–87
   PubMed Web of Science ®Google Scholar
• van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP, Heurkens AHM, Haanen HCM, Bijlsma JWJ. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. British Journal of Rheumatology. 1998; 37: 837–47
   PubMedGoogle Scholar
• van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP, van Albada–Kuipers GA, Hofman DM, Bijlsma JWJ, et al. Effect of rheumatoid arthritis on employment and social participation during the first years of disease in the Netherlands. British Journal of Rheumatology. 1998; 37: 848–853
   PubMedGoogle Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’ workshop contributors. Journal of Neurological Sciences. 1994; 124: S96–107
   PubMed Web of Science ®Google Scholar
• van den Berg JP, de Groot IJM, Joha BC, van Haelst JM, van Gorcom P, Kalmijn S. Development and implementation of the Dutch Protocol for Rehabilitative Management in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5: 226–9
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Costa J, Swash M. Clinical trials ALS: a review of the role of clinical and neurophysiological measurements. Amyotrophic Lateral Sclerosis. 2005; 6: 202–12
   PubMed Web of Science ®Google Scholar
• Hakkaart-van Roijen L. Manual Health and Labour Questionnaire. Institute for Medical Assessment 2000, Report number 00.52.
   Google Scholar
• Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardization of Costs: The Dutch Manual for Costing in Economic Evaluations. Pharmacoeconomics. 2002; 20: 443–54
   PubMed Web of Science ®Google Scholar
• Chiò A, Gouthier A, Vignola A, Calvo A, Ghiglione, Cavallo E, et al Caregiver time use in ALS. Neurology. 2006;67:902–4.
   PubMed Web of Science ®Google Scholar
• van den Berg JP, Niehoff A, Luijten R, van den Berg LH, Mathus-Vliegen LMH, Lindeman E, et al Differences in quality of life in amyotrophic lateral sclerosis patients with and without percutaneous endoscopic gastrostomy. Submitted.
   Google Scholar
• Callahan CM, Buchanan NN, Stump TE. Healthcare costs associated with percutaneous endoscopic gastrostomy among older adults in a defined community. J Am Geriatr Soc. 2001; 49: 1525–9
   PubMed Web of Science ®Google Scholar
• The ALS CNTF treatment study phase I-II Study Group; The Amyotrophic Lateral Sclerosis Functioning Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996;53:141–7.
   PubMedGoogle Scholar
• van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, van der Graaff MM, et al. Multidisciplinary ALS care improvews quality of life in patients with ALS. Neurology. 2005; 65: 1264–7
   PubMed Web of Science ®Google Scholar
• Goossens MEJB, Rutten MPMH, Vlaeyen JWS, van der Linden SMJP. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J of Clin Epidemiology. 2000; 53: 688–95
   PubMed Web of Science ®Google Scholar
• Klein LM, Forshew DA. The economic impact of ALS. Neurology. 1996; 47: S126–9
   PubMed Web of Science ®Google Scholar
• Corr B, Frost E, Traynor BJ, Hardiman O. Service provision for patients with ALS/MND: a cost-effective multidisciplinary approach. J of Neurol Sciences. 1998; 160: S141–5
   PubMed Web of Science ®Google Scholar
• Messori A, Trippoli S, Becagli P, Zaccara G. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Pharmacoeconomics. 1999; 16: 153–63
   PubMed Web of Science ®Google Scholar
• Tavakoli M, Malek M. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. J of Neurol Sciences. 2001; 191: 95–102
   PubMed Web of Science ®Google Scholar
• Wasner M, Klier H, Borasio GD. The use of alternative medicine by patients with amyotrophic lateral sclerosis. Journal of Neurological Sciences. 2002; 191: 151–4
   Web of Science ®Google Scholar
• Lechtzin N, Wiener CM, Clawson L, Chaudry V, Diette GB. Hospitalization in amyotrophic lateral sclerosis: causes, costs and outcomes. Neurology. 2001; 56: 753–7
   PubMed Web of Science ®Google Scholar
• Gray AM. ALS/MND and the perspective of health economics. J of Neurol Sciences. 1998; 160: S2–5
   PubMed Web of Science ®Google Scholar
• Heuts PH, de Bie R, Drietelaar M, Aretz K, Hopman-Rock M, Bastiaenen CH, et al. Self management in osteoarthritis of hip or knee: a randomized clinical trial in a primary healthcare setting. J Rheumatol. 2005; 32: 543–9
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry. 2003; 74: 1258–61
   PubMed Web of Science ®Google Scholar
• Chiò A, Bottacchi A, Buffa C, Mutani R, Mora G. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006; 77: 948–50
   PubMed Web of Science ®Google Scholar